Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) reached a new 52-week high during mid-day trading on Wednesday after Needham & Company LLC raised their price target on the stock from $154.00 to $169.00. Needham & Company LLC currently has a buy rating on the stock. Axsome Therapeutics traded as high as $167.22 and last traded at $173.5560, with a volume of 212985 shares changing hands. The stock had previously closed at $148.79.

Other analysts have also issued reports about the stock. Mizuho boosted their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating for the company in a research note on Tuesday, November 4th. Morgan Stanley raised their target price on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Guggenheim boosted their price target on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $183.94.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 10,558 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,071,193.22. This trade represents a 59.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 289,296 shares of company stock valued at $38,882,311. Corporate insiders own 22.30% of the company’s stock.

Key Stores Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: FDA granted priority review for AXS-05 (Auvelity) for agitation in Alzheimer’s disease — a faster review window increases the chance of an earlier approval and potential revenue upside if approved. Axsome stock surges after FDA grants priority review for Alzheimer’s drug
• Positive Sentiment: FDA accepted and granted priority review to Axsome’s supplemental New Drug Application for Auvelity in Alzheimer’s agitation — formal acceptance confirms the filing meets review standards and puts a PDUFA-like timeline on the calendar. Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug …
• Positive Sentiment: Company received formal FDA pre‑NDA meeting minutes for AXS‑12 (reboxetine) in narcolepsy and says an NDA submission is on track for January 2026 — advances another potential revenue stream and reduces regulatory execution risk. Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
• Neutral Sentiment: Multiple news outlets and analyst coverage highlighted the FDA action, amplifying investor attention and trading volume; media pieces explain why the stock is rallying but do not add new clinical data. Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer’s Agitation Drug
• Neutral Sentiment: Analyst activity: Needham raised its price target (from $154 to $169) and kept a Buy rating — a supportive read but the target is below the current trading level, so it’s not an unequivocal upside signal. Analyst price target update (Benzinga)
• Neutral Sentiment: Consensus analyst recommendation is roughly a “moderate buy,” reflecting optimism but also continued caution given Axsome’s history of negative earnings and reliance on successful approvals and launches. Axsome Therapeutics Given Average Recommendation of “Moderate Buy” by Analysts

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds have recently made changes to their positions in AXSM. Versant Capital Management Inc grew its holdings in Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares in the last quarter. First Horizon Corp purchased a new position in shares of Axsome Therapeutics in the third quarter valued at $34,000. Optiver Holding B.V. increased its position in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after purchasing an additional 130 shares during the last quarter. AlphaQuest LLC purchased a new stake in Axsome Therapeutics during the first quarter valued at $38,000. Finally, Essex Investment Management Co. LLC bought a new position in Axsome Therapeutics during the third quarter valued at $38,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Stock Up 22.8%

The firm has a market capitalization of $9.21 billion, a PE ratio of -39.11 and a beta of 0.44. The business’s 50 day simple moving average is $146.30 and its 200 day simple moving average is $124.92. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The business had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business’s revenue for the quarter was up 63.2% on a year-over-year basis. On average, equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.